I recently had the pleasure of attending the 18th annual Bio-IT world Conference and Expo at the Seaport World Trade Center in Boston with more than 3,000 researchers, bioinformaticians, and experts. My reason for attending the conference was that, during my analysis of some biotechnology companies as investments, I came to know that many of them are using proprietary algorithms that use technologies like artificial intelligence, AI, and data analytics to find the best therapeutic targets, for example, the neoantigens from a cancer patient's tumor biopsy, which might have the highest likelihood of eliciting T-cell